To include your compound in the COVID-19 Resource Center, submit it here.

Actimab-A: Additional Phase I/II data

Additional data from 12 previously untreated AML patients >=60 in cohorts 1-3 of an open-label, U.S. Phase I/II trial showed that Actimab-A

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE